{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:08:14Z","timestamp":1787987294111,"version":"build-2784847793"},"reference-count":119,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Molecular targeted tyrosine kinase inhibitors (TKIs) have produced unprecedented treatment response in cancer therapy for patients harboring specific oncogenic mutations. While the TKIs are mostly well tolerated, they were reported to increase serum levels of creatine kinase (CK) and cause muscle metabolism\u2010related toxicity. CK is an essential enzyme involved in cellular energy metabolism and muscle function. Elevated serum CK levels can arise from both physiological and pathological factors, as well as triggered by specific drug classes. The incidence of serum CK elevation induced by a few approved TKIs (brigatinib, binimetinib, cobimetinib\u2010vemurafenib combination [Food and Drug Administration, United States]; aumolertinib, and sunvozertinib [only approved by National Medical Products Administration, China]) were over 35%. CK elevation\u2010related symptoms include myopathy, myositis, inclusion body myositis (IBM), cardiotoxicity, rhabdomyolysis, rash, and acneiform dermatitis. High\u2010level or severe symptomatic CK elevation may necessitate dose reduction and indirectly dampen TKI efficacy. This review presents an updated summary about the prevalence rate and recent research about mechanisms leading to TKI\u2010induced serum CK elevation in cancer patients. The utility of monitoring serum CK levels for predicting TKI\u2010induced adverse effects and their management will also be discussed.<\/jats:p>","DOI":"10.1111\/cts.70053","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T07:22:33Z","timestamp":1730272953000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management"],"prefix":"10.1111","volume":"17","author":[{"given":"Hang","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine The Chinese University of Hong Kong  Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2755-0283","authenticated-orcid":false,"given":"Kenneth K. W.","family":"To","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine The Chinese University of Hong Kong  Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.83a.14120"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-011-0877-3"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01164"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.08.010"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211042271"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.23-00007"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.03.014"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100254"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-015-0674-9"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.09.009"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/030089161109700327"},{"key":"e_1_2_7_16_1","first-page":"1","article-title":"An unexpected and devastating adverse event of dasatinib: rhabdomyolysis","volume":"5","author":"Uz B","year":"2015","journal-title":"Leuk Res Rep"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.11.002"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0708896"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0656"},{"issue":"9","key":"e_1_2_7_20_1","article-title":"Long\u2010term efficacy and safety of brigatinib in crizotinib\u2010refractory ALK+ NSCLC: final results of the phase 1\/2 and randomized phase 2 (ALTA) trials","volume":"3","author":"Gettinger SN","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000481659"},{"key":"e_1_2_7_22_1","first-page":"47","article-title":"Rhabdomyolysis induced by the interaction between ribociclib and statins\u2010 case report and literature review","volume":"15","author":"Badran O","year":"2023","journal-title":"Breast Cancer"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00150"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1998.8.1029"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1998.8.1033"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10128"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1490-4"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2009.09.031"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.11.5089"},{"key":"e_1_2_7_30_1","first-page":"101","article-title":"The value of creatine kinase\/creatine kinase isoenzyme in differentiating myocardial injury from non\u2010myocardial injury","volume":"22","author":"Zhong RH","year":"2017","journal-title":"Chin J Hygiene Lab"},{"key":"e_1_2_7_31_1","first-page":"16","article-title":"The mechanism of skeletal muscle cell injury in sports","volume":"04","author":"Dongping C","year":"2007","journal-title":"J Xi'an Univ Arts Sci"},{"issue":"2","key":"e_1_2_7_32_1","first-page":"178","article-title":"The relationship between serum creatine kinase levels and clinical symptoms in patients with hypokalemic periodic paralysis","volume":"24","author":"Hua P","year":"2003","journal-title":"J Cap Med Univ"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-006-0701-0"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldm014"},{"issue":"6","key":"e_1_2_7_35_1","first-page":"1803","article-title":"Approach to the patient with hyperCKemia","volume":"22","author":"Venance SL","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7117.1219"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12067"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1734-1140(11)70601-6"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.01.003"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3764-2"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks416"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.035"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02738-5"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02659"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02088"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70024-X"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3019-5"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0297"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad086"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1814"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0204-1"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23788"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1971219"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11680"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13749"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02641"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.ijc_1374_21"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.06.013"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9002"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04557-0"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15121460"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac242"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0520"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3008"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12569"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01095-5"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00306"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3597-5"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.04.004"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1234262"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4443"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.334"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1331138"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00113"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.3223"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13623"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-05712-7.00004-0"},{"issue":"1","key":"e_1_2_7_83_1","article-title":"Life\u2010threatening myositis in a patient with EGFR\u2010mutated NSCLC on osimertinib: case report","volume":"3","author":"Crowley F","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.224"},{"issue":"37","key":"e_1_2_7_85_1","first-page":"79","article-title":"Cardiovascular toxicity associated with tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"1","author":"Binzaid AA","year":"2021","journal-title":"Gulf J Oncolog"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.2933.2933"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1314-5"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000891"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220945365"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.482"},{"key":"e_1_2_7_91_1","unstructured":"Genentech.Cotellic (cobimetinib).2015. U.S.Food and Drug Administration. Accessed September 27 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206192s005lbl.pdf"},{"key":"e_1_2_7_92_1","unstructured":"Array BioPharma.Mektovi (binimetinib).2018. U.S.Food and Drug Administration. Accessed September 27 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210498lbl.pdf"},{"key":"e_1_2_7_93_1","unstructured":"Array BioPharma.Braftov (encorafenib).2018. U.S.Food and Drug Administration. Accessed September 27 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/210496s014lbl.pdf"},{"key":"e_1_2_7_94_1","unstructured":"PharmaA.Xospata (gilteritinib).2018. U.S.Food and Drug Administration. Accessed September 27 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211349s001lbl.pdf"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq395"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-013-0381-2"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-916"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000690"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000424"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14778"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872020001101684"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2010.00823.x"},{"issue":"12","key":"e_1_2_7_103_1","article-title":"Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma","volume":"5","author":"Deken MA","year":"2016","journal-title":"Onco Targets Ther"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.03.066"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1414"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.020172"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2024.05.005"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113962"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-016-9386-7"},{"issue":"2","key":"e_1_2_7_110_1","first-page":"547","article-title":"The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review","volume":"15","author":"Muhammad DP","year":"2021","journal-title":"Oncol Rev"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-600"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02838-2"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01469-6"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2023.2259216"},{"key":"e_1_2_7_116_1","unstructured":"U.S. National Library of Medicine.IBRANCE \u2013 palbociclib capsule.2016. Kirkland Quebec: Pfizer Canada Inc. Accessed September 27 2024.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e0e6412f\u201050b4\u20104fd4\u20109364\u201062818d121a07"},{"key":"e_1_2_7_117_1","unstructured":"KISQALI\u00ae (ribociclib).Highlights of prescribing information. Accessed September 27 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda.docs\/label\/2019\/209092s004lbl.pdf"},{"key":"e_1_2_7_118_1","doi-asserted-by":"crossref","unstructured":"LuS LiC JianH et\u00a0al.Elevated creatine phosphokinase (CPK) as a strong predictor of aumolertinib (Au) treatment response in patients (pts) with advanced non\u2010small cell lung cancer (NSCLC): post\u2010hoc analysis of AENEAS. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14\u201319; Orlando FL. Philadelphia (PA): AACR; Cancer Res 2023; 83(7_Suppl): Abstract nr 5462.","DOI":"10.1158\/1538-7445.AM2023-5462"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.405"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.411"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T07:17:56Z","timestamp":1732605476000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":119,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/cts.70053"],"URL":"https:\/\/doi.org\/10.1111\/cts.70053","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"2024-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70053"}}